Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Measles mumps and rubella virus vaccine - GlaxoSmithKline

Next Previous
Search
Drug Profile

Measles mumps and rubella virus vaccine - GlaxoSmithKline

Alternative Names: 209762; GSK-209762; MMR vaccine - Bio-Manguinhos; MMR vaccine - GlaxoSmithKline; Priorix; SB-209762

Latest Information Update: 21 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; GSK
  • Class Measles vaccines; Mumps vaccines; Rubella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Measles; Mumps; Rubella

Most Recent Events

  • 03 Mar 2025 GlaxoSmithKline plans a phase III trial for Varicella zoster virus infections (In infants, Prevention) in April 2025 (IM, Injeciton) (NCT01991899)
  • 03 Dec 2024 Preregistration for Measles (In children, Prevention) in USA (SC)
  • 03 Dec 2024 Preregistration for Measles (In infants, Prevention) in USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top